Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity
- 1 April 1997
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 61 (1-2) , 97-106
- https://doi.org/10.1016/s0960-0760(97)00008-3
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal womenJournal of Bone and Mineral Research, 1996
- The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal WomenNew England Journal of Medicine, 1995
- Estrogen Replacement Therapy in Older WomenArchives of Neurology, 1994
- Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.Journal of Clinical Investigation, 1994
- The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly WomenNew England Journal of Medicine, 1993
- Postmenopausal Estrogen Therapy and Cardiovascular DiseaseNew England Journal of Medicine, 1991
- Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride (LY 156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicityJournal of Medicinal Chemistry, 1984
- Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levelsLife Sciences, 1983
- Increased Risk of Endometrial Carcinoma among Users of Conjugated EstrogensNew England Journal of Medicine, 1975
- Association of Exogenous Estrogen and Endometrial CarcinomaNew England Journal of Medicine, 1975